Abstract 620: Screening of small-molecule MAPK pathway inhibitors on a panel of 130 human cancer cell lines identifies determinants of response in RAS -mutant subgroups
Kooijman, Jeffrey J., Al Koerdi, Awan, Kluitmans, Daphne J., van den Bossche, Esmee, Dylus, Jelle, de Roos, Jeroen A., Melis, Janneke J., Zaman, Guido J.
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract A100: Large-scale cell line profiling of small molecule MAPK pathway inhibitors identifies important differences between therapeutics acting on the same biochemical target
Kooijman, Jeffrey J., Koerdi, Awan Al, van Riel, Wilhelmina E., Bossche, Esmee van den, Dylus, Jelle, de Roos, Jeroen A.D.M., Melis, Janneke J.T.M., Zaman, Guido J.R.
Published in Molecular cancer therapeutics (01.12.2023)
Published in Molecular cancer therapeutics (01.12.2023)
Get full text
Journal Article
Abstract 619: Comprehensive cell line profiling of monomer- and dimer-selective small molecule RAF inhibitors uncovers determinants of cellular responses
Kooijman, Jeffrey J., Koerdi, Awan Al, van der Leeuw, Sjoerd B., Kluitmans, Daphne J., van den Bossche, Esmee, Dylus, Jelle, de Roos, Jeroen A., Melis, Janneke J., Willemsen-Seegers, Nicole, Zaman, Guido J.
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article